Initial chemotherapy option for pancreatic ductal adenocarcinoma in patients with adequate performance status  

作　　者：Jiazhang Xing Yuping Ge Xiaolei Gong Yuan Liu Yuejuan Cheng 

机构地区：[1]Department of Medical Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing,China

出　　处：《Journal of Pancreatology》2023年第4期196-201,共6页胰腺病学杂志（英文）

摘　　要：Pancreatic ductal adenocarcinoma(PDAC)is a highly progressive lethal malignancy,with chemotherapy being the primary treatment modality.This article provides a review of the initial chemotherapy options for PDAC patients with adequate performance status,comparing FOLFIRINOX(oxaliplatin,irinotecan,5-fluorouracil,and leucovorin)or modified FOLFIRINOX and gemcitabine plus nab-paclitaxel(GEM-NabP)regimens.The availability of limited evidence from randomized trials restricts a direct comparison between the 2 regimens.Based on our review,(m)FOLFIRINOX yields superior survival outcomes compared to GEM-NabP in metastatic PDAC.For locally advanced PDAC,either(m)FOLFIRINOX or GEM-NabP can be considered initial chemotherapy.In the neoadjuvant setting for borderline resectable PDAC,both regimens have demonstrated promising results in achieving feasible resection rates.However,mFOLFIRINOX remains the preferred choice for adjuvant chemotherapy.The selection of initial chemotherapy for PDAC depends on the disease stage,patients’performance status,and tumor molecular alterations.Further research and clinical trials are necessary to optimize treatment approaches for PDAC patients.

关 键 词：FOLFIRINOX Gemcitabine plus nab-paclitaxel Pancreatic ductal adenocarcinoma 

分 类 号：R735.9[医药卫生—肿瘤]